Pharmaron Beijing Co., Ltd.
300759
Rank in Stocks
#2354
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a... Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Share Price
$5.58
Market Cap
$8.24B
Change (1 day)
-3.77%
Change (1 year)
28.36%
Country
CN
Trade Pharmaron Beijing Co., Ltd. (300759)
Category
Healthcare
P/E ratio for Pharmaron Beijing Co., Ltd. (300759)
P/E ratio as of October 2026 TTM: 38.39
According to Pharmaron Beijing Co., Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 38.39. At the end of 2024 the company had a P/E ratio of 25.36.
P/E ratio history for Pharmaron Beijing Co., Ltd. from 2014 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 38.39 | 26.96% |
| 2025 | 30.24 | 19.25% |
| 2024 | 25.36 | -21.07% |
| 2023 | 32.13 | -45.04% |
| 2022 | 58.47 | 95.59% |
| 2021 | 29.89 | -17.12% |
| 2020 | 36.07 | 31.24% |
| 2019 | 27.48 | 204.91% |
| 2018 | 9.01 | -52.17% |
| 2017 | 18.85 | -10.26% |
| 2016 | 21.00 | -37.39% |
| 2015 | 33.54 | -71.57% |
| 2014 | 117.97 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 30.83 | -19.69% |
US
|
|
| -29.16 | -175.96% |
US
|
|
| -25.99 | -167.70% |
AU
|
|
| 22.43 | -41.57% |
BE
|
|
| 31.22 | -18.69% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.